Search Results - therapeutic+matter

408 Results

Sort By:

Non-intuitive combination of drug delivery carriers of the same drug for synergistic growth delay of solid tumors

Non-intuitive combination of drug delivery carriers of the same drug for synergistic growth delay of solid tumorsJHU Ref #: C15411 Unmet NeedCancer is the second leading cause of death in the United States, with an estimated 1.8 million cases having been diagnosed and 606,520 people having succumbed to the disease in 2020. The most common cancer diagnosis...

Published: 4/24/2026 | Inventor(s): Stavroula Sofou, Alaina Howe

Keywords(s): Breast Cancer, Cancers, Disease Indication, Drug Delivery Vehicle, Nanoparticles, Therapeutic Matter, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Clinical and Disease Specializations > Oncology

Compositions and Methods for Treatment of Eye Diseases

Unmet NeedOxidative stress contributes to the progression of multiple eye disorders, including retinitis pigmentosa, age-related macular degeneration, and diabetic retinopathy. Ocular oxidative stress is caused by an imbalance of antioxidants and pro-oxidants in the eye, leading to elevated levels of free radicals. Free radicals contribute to the damage...

Published: 4/24/2026 | Inventor(s): Peter Campochiaro, Andrea Cook

Keywords(s): Disease Indication, Eye Disorders, Non-novel, Predicted Novelty, Retinitis pigmentosa, Single, Therapeutic Matter, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations > Neurology > Neurodegeneration, Clinical and Disease Specializations > Ophthalmology > Retinitis Pigmentosa, Clinical and Disease Specializations > Rare Diseases

Combinations of ASOs for the Modulation of SMN Expression in SMA Patients

Unmet NeedSpinal muscular atrophy (SMA) is a devastating neuromuscular disease that predominantly affects children and is the most common cause of hereditary infant mortality. The disease is caused by low levels of survival motor neuron (SMN) protein, due to recessive mutations in the SMN1 gene. Importantly, the copy number variation of SMN2, a homologous...

Published: 4/24/2026 | Inventor(s): Charlotte Sumner, Constantin d'Ydewalle, Frank Rigo, C. Bennett

Keywords(s): CNS and Neurological Disorders, Combination, Disease Indication, Drug Delivery Vehicle, Muscle Atrophy, Muscular Disorders, Neurodegenerative Diseases, Peptides/Prodrugs, Single, Targeted Therapy, Therapeutic Matter, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations > Neurology > Motor Neuron Diseases, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities > Proteins

Novel HPV Vaccine

C10218: L2 Lipopeptide Vaccine for Prevention of Human Papillomavirus Infection Value Proposition: • A broadly protective vaccine against HPV. • Can be delivered without needles. • Can be chemically synthesized at low cost. Technical Details: Human papillomavirus (HPV) infections are the most common sexually transmitted infection in the...

Published: 4/23/2026 | Inventor(s): Hannah Alphs-Jackson, Ratish Gambhira, Richard Roden

Keywords(s): Biologics, Cancers, Disease Indication, Therapeutic Matter, Therapeutic Substance, Therapeutics, Vaccine

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Vaccines, Technology Classifications > Therapeutic Modalities

Co-assembling Peptide Hydrogels

The compositions and methods disclosed herein pertain to the manufacture and use of hydrogels. The disclosed compositions and methods pertain to hydrogels capable of induction by a variety of methodologies, such as by pH, salt and/or mixing. Such hydrogels are capable of self- or co-assembly and while doing so, may entrap a variety of bioactive agents...

Published: 4/23/2026 | Inventor(s): Yihua Yu, Sivakumar Ramachandran, Peter Flynn, Yiider Tseng

Keywords(s): Drug Delivery Vehicle, Hydrogel, Therapeutic Matter, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities

New therapeutic approach for the treatment of neuropathic pain

Unmet NeedChronic pain affects around 50-million adults within the United States (see CDC). Currently the dominant treatment option for moderate to severe pain are opioids, which have a range of associated adverse effects as well as the potential for abuse. Despite the development of abuse-deterrent formulations, opioid dependence remains a major challenge....

Published: 4/24/2026 | Inventor(s): Takashi Tsukamoto, Barbara Slusher, Niyada Hin, Camilo Rojas, Xinzhong Dong, Yun Guan, Ilyas Berhane

Keywords(s): Agonists/Promoters, Chronic Pain, CNS and Neurological Disorders, Disease Indication, Small Molecules, Target, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations > Pain > Chronic Neuropathic Pain, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities > Small Molecules

Out for review, Need to check with Tulane whether we can post it or not.

Unmet Need There are significant roadblocks to the routine delivery of macromolecules such as proteins, peptides, imaging agents, polysaccharides and more to the cytosol of mammalian cells. While most macromolecules are easily directed to existing cellular uptake mechanisms, they are often trapped in endosomal pathways leading to lysosomal degradation...

Published: 4/24/2026 | Inventor(s): Kalina Hristova, Gregory Wiedman, William Wimley, Sarah Kim

Keywords(s): Biologics, Drug Delivery Vehicle, Peptide, Peptides/Prodrugs, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Peptides, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities

Targeting of Myeloid-Derived Suppressor Cells (MDSCs) for Cancer Treatment

Value Proposition· Addresses key resistance mechanism: targets MDSCs, a central driver of resistance to immune checkpoint inhibitors in metastatic and poorly immunogenic cancers· Synergistic combination strategy: Combines epigenetic modulators (HDAC and DNA methyltransferase inhibitors) with anti-PD-1 and anti-CTLA-4 antibodies to restore...

Published: 4/23/2026 | Inventor(s): KiBem Kim, Bert Vogelstein, Kenneth Kinzler, Shibin Zhou

Keywords(s): Antagonists/Inhibitors, Antibodies, Biologics, Cancers, Combination, Disease Indication, Non-novel, Predicted Novelty, Repurposed, Small Molecules, Targeted Therapy/Immunotherapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities

PSMA-targeting nanoparticle for prostate cancer therapy

PSMA-targeting nanoparticle for prostate cancer therapyJHU Ref #: C10180Value Proposition:· Engineered nanoparticle system with potent urea-based PSMA inhibitor· Drug loaded nanoparticle· Specific and selective tumor cytotoxicity Unmet NeedProstate cancer affects millions of men globally and is a leading cause of cancer death in...

Published: 4/23/2026 | Inventor(s): Martin Pomper, Ronnie Mease, Sachin Chandran, Sangeeta Ray, Samuel Denmeade

Keywords(s): Cancers, Disease Indication, Drug Delivery Vehicle, Nanoparticles, Prostate Cancer, Single, Targeted Therapy, Therapeutic Matter, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Men's Health, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities > Targets, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Prostate Cancer

Targeted chemo-immunotherapy delivery

Value PropositionEnhanced effect of immunotherapyTreatment for recurrent or metastatic diseaseImproved glioma treatment Unmet NeedImmunotherapy represents a new paradigm in cancer treatment. Molecules that effectively reverse the immune suppressing nature of cancer have the potential to enhance the body’s ability to work systemically combat cancer (Pardoll,...

Published: 4/23/2026 | Inventor(s): Dimitrios Mathios, Betty Tyler, Drew Pardoll, Henry Brem, Michael Lim

Keywords(s): Antagonists/Inhibitors, Cancers, Chemotherapy/Immunotherapy, Combination, Disease Indication, Non-novel, Predicted Novelty, Repurposed, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Immunology, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities

1 2 3 4 5 6 7 8 9 10 ...